When the Trump administration accused China of “unfairly” using venture capital to acquire technologies last month, it singled out the firm 6 Dimensions Capital, calling it a suspicious agent of the Chinese government bent on acquiring U.S. biotechnology.
That came as a surprise to 6 Dimensions’ CEO, Leon Chen, who said neither he nor anyone at his firm had ever been contacted by the U.S. trade representative, which issued the report naming his firm.
To Chen, the accusation was absurd. All five managing partners at 6 Dimensions are naturalized U.S. citizens. One of them, Wei Li of Boston, has lived in the U.S. since 1993. And the money his firm invests in U.S. companies comes almost entirely from outside of China.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
